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Uremia induces the osteoblast differentiation factor Cbfa1 in quire dialysis, at a risk that is 10- to 20-fold greater than
human blood vessels. the general population [4, 5]. Studies evaluating coronary
Background. Bone matrix proteins are expressed in calcified calcification by EBCT in patients with ESRD have dem-arteries from dialysis patients, suggesting that vascular smooth
onstrated excessive coronary artery calcification, even inmuscle cells (VSMCs) may transform to osteoblast-like cells.
young adults [6, 7]. Pathologic analysis of arteries fromOne of the key transcriptional regulators of osteoblast differen-
tiation is Cbfa1. Thus, we hypothesized that this may be a key nondialysis patients demonstrates that vascular calcifi-
factor in arterial calcification. cation resembles developmental bone mineralization,
Methods. To test this hypothesis, we examined sections of with the production of “bone” proteins by vascular smooththe inferior epigastric artery from uremic patients for the pres-
muscle cells (VSMCs), such as osteopontin, bone sialo-ence of Cbfa1 and type I collagen and osteopontin by in situ
hybridization and immunostaining. We also examined the ef- protein, alkaline phosphatase, and type I collagen [8–11].
fect of pooled uremic sera from dialysis patients on the expres- We have confirmed these findings in arteries from dial-
sion of Cbfa1 by reverse transcription-polymerase chain reac- ysis patients [12, 13]. This would imply that the calcifica-
tion (RT-PCR) in bovine VSMCs in vitro.
tion of vascular tissue is an active process, with VSMCsResults. Cbfa1 and osteopontin were expressed in both the
transforming to osteoblast-like cells. However, the mech-media and the intima in vessels that were calcified, but there
was only minimal staining in non-calcified vessels. In vitro anism by which this occurs is not yet clear.
studies demonstrated that pooled uremic serum, compared to In vitro experiments in both human and bovine
pooled control human serum induced the expression of Cbfa1 VSMCs have demonstrated that phosphorus, in the formby RT-PCR in bovine VSMCs in a time-dependent, nonphos-
of -glycerophosphate (which is cleaved by alkaline phos-phorus-mediated mechanism.
phatase to form free phosphate), can induce calcificationConclusion. These results support that Cbfa1 is a key regula-
tory factor in the vascular calcification observed in dialysis similar to that observed in osteoblast cultures [14, 15].
patients and is up-regulated in response to many uremic toxins. The mechanism by which phosphorus induced calcifica-
tion was dependent on the sodium-phosphate (Na/Pi)
co-transporter [16]. Furthermore, in a recent study by
The assessment of coronary arteries by new noninva- Jono et al [17], exogenous phosphate added to human
sive imaging techniques such as electron beam computed VSMCs culture up-regulated Cbfa1 expression. Cbfa1 is
tomography scan (EBCT) and intracardiac ultrasound a transcription factor critical for osteoblast differentiation
has heightened the awareness that over 70% of athero- and the expression of the bone matrix proteins, osteo-
sclerotic plaques observed in the aging population are pontin, osteocalcin, and type I collagen [18]. In addition,
calcified [1], and the magnitude of calcification correlates Cbfa1 knockout mice fail to form mineralized bone,
with the severity of obstructive coronary artery disease proving that Cbfa1 is critical for the terminal differentia-
by angiography and clinical events [2, 3]. Cardiovascular tion of osteoblasts [19]. Thus, the in vitro data in VSMCs
disease and stroke are the leading causes of death in support that phosphorus can lead to calcification, and
patients with end-stage renal disease (ESRD) that re- that phosphorus can induce Cbfa1 and the expression of
bone matrix proteins. However, in vivo evidence of this
relationship to vascular calcification is lacking. We haveKey words: Cbfa1, vascular calcification, osteopontin, type 1 collagen,
dialysis. previously demonstrated that pooled serum collected
from hemodialysis patients can also induce mineraliza-Received for publication August 16, 2002
tion of bovine VSMCs to a greater extent and at anand in revised form October 4, 2002
Accepted for publication October 17, 2002 earlier time point than bovine VSMCs incubated with
pooled serum from healthy controls [20]. In addition, 2003 by the International Society of Nephrology
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(7 ) were utilized for both immunohistochemistry anduremic serum can induce osteopontin protein expression
in situ hybridization.in bovine VSMCs at levels twofold that induced by con-
Immunostaining was performed on frozen cryostattrol serum, despite similar final media concentrations of
sections that were mounted onto treated glass slides (Su-phosphorus of 0.5 to 0.6 mmol/L [20], which is markedly
perfrost/plus, Fisher Scientific, Pittsburgh, PA, USA),less than concentrations of phosphorus that have been
post-fixed in 4% paraformaldehyde for 10 minutes atpreviously shown to upregulate Cbfa1 expression in cul-
4C, and washed in phosphate-buffered saline (PBS) fol-tured VSMCs [17]. Furthermore, the addition of exoge-
lowed by deionized H2O. The sections were incubatednous phosphorus in the form of -glycerophosphate dou-
for 10 minutes in hydrogen peroxide, followed by block-bled osteopontin expression in bovine VSMCs incubated
ing with 1.5% blocking serum in PBS (Santa Cruz Bio-with control serum, but had no additive effect in bovine
technology, Santa Cruz, CA, USA) for 1 hour. The sec-VSMC incubated with uremic serum [20]. These data
tions were incubated with the primary antibody againstsuggest that uremic serum, regardless of the phosphorus
Cbfa1 (a gift from Dr. Gerald Karsenty, Baylor Collegeconcentration, can induce bovine VSMC to become osteo-
of Medicine, Houston, TX; 1:300 dilution). To confirm
blast-like cells, capable of mineralization and production our findings, two additional Cbfa1 antibodies were used
of bone matrix proteins. We, therefore, hypothesized (Santa Cruz Biotechnology and Oncogene, Boston, MA,
that nonphosphorus uremic toxins may also lead to the USA), both at 1:10 dilution for 1 hour. The sections
up-regulation of Cbfa1 with subsequent expression of were developed by the aviding-biotin-complex (ABC)
bone matrix proteins in vascular tissue, resulting in calci- staining system (Santa Cruz Biotechnology), followed
fication. by color development with 3,3 diaminobenzaidine tetra-
This report describes the novel finding of ex vivo ex- hydrochloride (DAB). Sections were counterstained with
pression of Cbfa1 in both medial and intimal calcification hematoxylin. Negative controls were obtained by substi-
of arteries from dialysis patients. Furthermore, pooled tuting the primary antibody with PBS. To determine if
serum from dialysis patients can induce expression of the downstream proteins of Cbfa1 transcription were
Cbfa1 in bovine VSMCs in vitro through a nonphospho- also up-regulated, immunostaining for type I collagen
rus-dependent mechanism. These data implicate Cbfa1 and osteopontin (gifts of Larry Fisher, Ph.D; National
Institutes of Health; 1:100 dilution) was similarly per-as a potential regulatory factor important in vascular
formed. The presence of macrophages was determinedcalcification in dialysis patients.
utilizing anti-CD68 antibody (Dako, Carpenteria, CA).
Images were recorded on a digital camera (Nikon Cool-
METHODS pix 950) using a Nikon Eclipse E400 microscope through
10 or 40 objective (1.4 numerical aperture). SectionsTo test the hypothesis that uremia up-regulates the
were also examined by MacNeal’s stain (toluidine blueexpression of Cbfa1, we performed two sets of experi-
with silver stain) to assess calcification as previously de-ments: (1) ex vivo examination of sections of the inferior
scribed [13].epigastric artery (obtained from patients undergoing re-
In situ hybridization was performed on the same fro-nal transplantation) by in situ hybridization for Cbfa1,
zen sections of the inferior epigastric artery prepared asand immunostaining for Cbfa1, type I collagen, and osteo-
above. Sections were treated with 1 N HCl for 10 minutespontin; and (2) in vitro determination of Cbfa1 expression
followed by 0.1 mol/L Triethanolamine (TEA) bufferin bovine VSMC by reverse transcription-polymerase
for 20 minutes. The specimens were prehybridized for 2chain reaction (RT-PCR). The cells were incubated with
hours at 42C and hybridized with the labeled riboprobepooled sera collected from control (nonuremic) individu-
(5 ng/uL) for 16 hours. Riboprobes were made by inals or dialysis patients on hemodialysis for at least 2 years
vitro transcription of linearized plasmids (pBluescriptto eliminate any residual renal function. Both studies
SK) containing cDNA for Cbfa1 [American Type Cul-
were approved by the local Institutional Review Board ture Collection (ATCC), Manassas, VA, USA]. In vitro
and all patients gave written informed consent. transcription was performed in the presence of digoxy-
genin-uridine triphosphate (dUTP) and T3 RNA poly-Ex vivo studies
merase (antisense probe) or T7 RNA polymerase (sense
The inferior epigastric artery was obtained from pa- probe), according to the manufacturer’s instruction (Roche
tients undergoing renal transplantation as previously de- Diagnostics, Indianapolis, IN, USA). Specimens were
scribed [13]. Briefly, during the surgery, the proximal washed under stringent conditions. After hybridization,
inferior epigastric artery is normally ligated. For the pres- sections were washed for 30 minutes in 2 SSC at room
ent study, a 2 to 3 cm piece of vessel was removed and temperature and then 1 hour each in 1 standard sodium
placed in 4% paraformaldehyde, then snap frozen in citrate (SSC), 0.5 SSC, and 0.1 SSC in the presence
22-oxacalcitriol (OCT) embedding compound (Triangle of 50% formamide at 48C. Probe binding was localized
by a colorimetric reaction with an alkaline phosphatase-Biomedical Science, Durham, NC, USA). Cryosections
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conjugated antidigoxygenin antibody (Roche Diagnostics, as previously described [20]. Briefly, medial tissue was
separated from segments of bovine aorta after removalIndianapolis, IN, USA). Methylgreen was used for coun-
terstaining. For negative controls serial sections were of endothelial cells. Small pieces of tissue (1 mm2) were
placed in a 6-well culture dish and cultured for 2 weeksprocessed using sense probe.
Laser capture microdissection. Tissue samples were in Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma
Chemical Company, St. Louis, MO, USA) containingselectively dissected using the PixCell II Laser Capture
System (Arcturus, Mountain View, CA, USA). Briefly, 4.5 g/L glucose supplemented with 10% fetal bovine
serum (FBS; Sigma) in a 95%/5% air/CO2 humidifiedcryosections were sliced at a 7m thickness and mounted
on HistoGene laser capture microdissection (LCM) environment at 37C. Cells that migrated from the ex-
plants were collected and maintained in DMEM con-Slides (Arcturus). Slides were then stained using the
HistoGene LCM Frozen Section Staining Kit (Arc- taining 10% FBS with 100 U/mL penicillin and 100 g/mL
streptomycin. The media was replaced every 2 to 3 days.turus) in order to maintain RNA integrity. Once com-
pletely dry, the stained sections were brought to focus Only cells between passages 2 to 8 were used for experi-
ments [14]. In order to determine whether acceleratedon the microscope and the section of interest was covered
with the LCM cap. The laser was focused and intensity vascular calcification in dialysis patients is due to the
induction of Cbfa1 expression, bovine VSMCs were incu-varied based on slide conditions. The 30 m diameter
laser pulse setting was used to melt areas of the LCM bated for 24 or 48 hours with DMEM plus 10% uremic
serum from dialysis patients (see below) or healthy con-cap film, adhering those cells directly beneath to the cap
surface. The harvested cells were then digested from the trol patients and analyzed by RT-PCR. -actin was used
as an internal control.cap and the total RNA was purified using the PicoPure
RNA Isolation Kit (Arcturus). RNA was eluted twice Uremic sera were pooled from patients who were on
dialysis for at least 2 years to eliminate residual renalfrom the provided column. RNA was harvested from 4
to 6 consecutive sections per patient and pooled for RT- function. Sera from normal healthy individuals of similar
ages served as controls. The sera were pooled and frozenPCR. A similar caliber vessel (superior epigastric artery)
was obtained from a patient undergoing a Whipple’s at –20C in aliquots for use in tissue culture. The pooled
sera were analyzed for pH by Corning pH meter 240;procedure and similarly processed. The subject did not
have renal failure or diabetes, but was elderly and had total alkaline phosphatase, electrolytes, calcium, and
phosphorus by chemistry autoanalyzer (Roche Diagnos-calcification of the aorta present on CT scan, suggesting
the presence of atherosclerosis. Unfortunately, we were tics); parathyroid hormone (PTH) by intact assay (Nich-
ols Laboratory, San Juan Capistrano, CA); bone alkalinenot able to obtain a truly healthy young vessel of similar
caliber. phosphatase by enzyme-linked immunosorbent assay
(ELISA) (Metra Biosystems, Mountain View, CA, USA);RT-PCR was performed using Titan One Tube RT-
PCR Kit (Roche Diagnostics, Indianapolis, IN, USA). and C-reactive protein by ELISA (Alpha Diagnostics,
San Antonio, TX, USA). Ten percent of the control orBriefly, total RNA was isolated by LCM, and reverse-
transcribed at 50C for 30 minutes followed by PCR uremic serum was added to media for use with cell cul-
ture. The phosphorus concentration of the final mediareaction with Titan enzyme mix [avian myeloblastosis
virus (AMV) reverse transcriptase and Taq DNA poly- plus 10% serum was measured using a colorimetric
method (Sigma Chemical Company).merase] in a 50L mixture containing 0.2 mmol/L desox-
ynucleoside triphosphate (dNTPs), 5 U RNAse inhibitor,
Statistical analysis5 mmol/L dithiothreitol (DTT), 20 pmol sense and anti-
The immunohistochemistry and in situ hybridizationsense primers. The sense primer for Cbfa1 was 5-CCG
tissue sections were read semiquantitatively by a singleCACGACAACCGCACC-3; the Cbfa1 antisense primer
reader (0  no staining; 1  scattered positive cells;was 5-CGCTCCGGCCCACAAATC-3. The reaction
2  small patches positive cells; 3  diffuse patcheswent for 35 cycles consisting of 30 seconds at 94C, 30
positive staining; 4  entire medial layer positive).seconds at 55C, and 1 minute at 68C, followed by a
The RT-PCR was quantified by densitometry, and thefinal extension step at 68C for 7 minutes before cooling
difference in the Cbfa1/-actin ratio between the groupsat 4C. The RT-PCR products were resolved on a 1.5%
compared by analysis of variance (ANOVA) with Fish-agarose gel and visualized by ethidium bromide staining.
The housekeeping gene -actin was used for internal er’s post-hoc analysis (StatView, SAS Institute, Inc.,
control. The band density was analyzed by scanning den- Cary, NC, USA); P  0.05 was considered significant.
sitometry (Molecular Analysis, Bio-Rad, Richmond, CA,
USA). RESULTS
Ex vivo examination of the inferior epigastric arteryIn vitro studies
Bovine VSMCs were obtained by a modification of As previously described, 41 inferior epigastric arteries
were obtained and examined for immunohistochemistrythe explant method originally described by Ross [21]
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Fig. 1. Histopathologic analysis of vascular calcification in the inferior epigastric artery from dialysis patients. The left two columns are sections
from an artery from Patient 1, a 40-year-old diabetic on hemodialysis for 24 months. This vessel demonstrates calcification adjacent to an intimal
plaque (arrow) and in the media (arrowhead; 10) (A). Abbreviations are: I, intima; M, media; P, plaque). (B) shows the boxed area from (A)
at a higher magnification (40) demonstrating the calcification surrounds the cells and is located in the area between cells. The results from this
3 calcified vessel in (A) are compared to the results from Patient 4, a 55-year-old on dialysis for 14 months with only 0.5  calcification (C). The
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for the expression of various bone matrix proteins, in-
cluding type I collagen and osteopontin, downstream
protein products induced by Cbfa1 activation. This pro-
tein expression was present in vessels without calcifica-
tion, suggesting that deposition of bone proteins pre-
ceded overt calcification [10]. Eight of these vessels were
also prepared as frozen sections and were utilized for
the present study. These vessels showed various levels
of calcification by MacNeal’s stain, (three vessels with
no calcification; four vessels with 0.5 to 2 calcification;
one vessel with 3 calcification).
Examination of the vessels by in situ hybridization
demonstrated two vessels with positive Cbfa1 staining
in the intima; both of these had thickened intima, with
other cells positive for the macrophage marker CD68.
One of these vessels had an intimal plaque. The other
six vessels had nonthickened intima and no expression
Fig. 2. Reverse transcription-polymerase chain reaction (RT-PCR) ofof Cbfa1 or CD68 staining in the intima. In contrast, in total RNA isolated from vessel section by laser capture microdissection
the medial layer, there was no expression of CD68 by (LCM). Sections from four vessels from end-stage renal disease (ESRD)
patients, and one vessel from a non-ESRD patient were utilized forimmunostaining but positive expression for Cbfa1 by in
total RNA isolation by laser capture microdissection (see Methods
situ hybridization in all eight vessels. Four vessels had section). The results of the ratio of Cbfa1 to -actin, assessed by densi-
tometry, are shown graphically. RT-PCR was performed from totalonly scattered Cbfa1 positive cells by in situ hybridiza-
RNA isolated from 4 to 6 consecutive sections of vessel per patient.tion (1); the remaining four vessels had more patchy
Patient 1, due to the extensive calcification, had many fewer viable cells
expression (2 to 3). Qualitative results of immunostain- for the same amount of tissue collected. These studies parallel the
results of the in situ hybridization (Cbfa1 in situ), calcification score bying for Cbfa1 paralleled the RNA expression of Cbfa1
MacNeal’s stain (Calcif score), and immunostaining for osteopontinin both the intima and the medial layers. The staining
and type I collagen (Type I collagen).
pattern was similar with all three Cbfa1 antibodies, al-
though expression was best visualized with the antibody
that corresponds to the 17 amino acids of the N-terminals
portion of Cbfa1 (a gift from Dr. Gerard Karsenty). panels) is compared to a minimally calcified vessel with
only scattered Cbfa1 positive cells in the medial layerThe location and scoring for the immunostaining for the
Cbfa1-induced downstream proteins osteopontin and (Patient 4; right panel).
To confirm the in situ hybridization results, total RNAtype I collagen parallel the Cbfa1 expression by in situ
hybridization and immunostaining. Of note, this expres- was isolated from available sections of vessels of Patients
1 through 4 by laser capture microdissection. RT-PCRsion of Cbfa1 and its downstream proteins was found
even in areas of sections without overt calcification. This was performed and the Cbfa1 expression was normalized
to -actin. These results and corresponding results forsuggests that this transformation of VSMCs to osteo-
blast-like cells with deposition of matrix proteins occurs calcification, in situ hybridization, and immunostaining
for osteopontin and type I collagen are shown in Figurebefore overt calcification by up-regulation of Cbfa1.
These results are further demonstrated in Figure 1 where 2. The results demonstrate that in Patients 1 and 2, where
calcification was present, there was greater Cbfa1, osteo-expression in a vessel with both intimal and medial calci-
fication and strong Cbfa1 expression (Patient 1; left two pontin, and type I collagen expression than in Patients

first row is the vessels stained by MacNeal’s tetrachrome stain, where calcification is indicated by a black color. In contrast, the vessel from Patient
4 in (C) shows only scattered spots of faint calcification (arrow; 10). In situ hybridization for Cbfa1 expression demonstrates significant expression
in both the intima and media of the vessel from Patient 1 (D) (10). The negative control (sense probe) is shown in (E ) (10). Higher magnification
of Cbfa1 expression by in situ hybridization is shown for the intima (G ) (40) and media (H ) (40). In contrast, in the vessel from Patient 4,
there is very little expression of Cbfa1 by in situ hybridization with only scattered positive cells (F ) (10) and (I ) (40). Immunostaining using
an anti-Cbfa1 antibody paralleled the findings of in situ hybridization in the calcified vessel in both the intima (J ) (40) and media (K ) (40) of
vessel from Patient 1. In contrast, there was no detectable immunostaining for Cbfa1 in the vessel from Patient 4 (L ) (40). Up-regulation of
Cbfa1 leads to the expression of the downstream bone matrix proteins osteopontin and type I collagen. Immunostaining for osteopontin demonstrated
expression in areas also positive for Cbfa1 in both the intima (M ) (40) and media (N ) (40) of vessel from Patient 1. In contrast, there was
minimal expression of osteopontin in the vessel with minimal Cbfa1 expression (O) (arrow) (40). Similar results were demonstrated with type
I collagen where immunostaining was similarly localized in both the intima (P ) (40) and media (Q ) (40) in the vessel from Patient 1, whereas
there was essentially no expression of type I collagen in the area without Cbfa1 expression in the minimally calcified vessel (R) (40).
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Table 1. Results of analysis of pooled serum
Control sera Uremic serum
Number of patients 14 13
Age years 48.7 46.2
Gender %F 36 46
Hemodialysis years — 6.9
Diabetic % — 23
Vitamin D usage % — 23
Kt/V — 1.45
Sodium meq/L 142 140
Potassium meq/L 4.3 5.1
Albumin g/L 48 40
pH 8.05 8.15
Calcium mmol/L 2.3 2.1
Phosphorus mmol/L 1.13 2.39
Parathyroid hormone pmol/L 2.8 49.6
Total alkaline phosphatase IU 62 155 Fig. 3. Effect of phosphorus on uremic serum induced Cbfa1 expres-
Bone alkaline phosphatase IU 11.3 40 sion. Reverse transcription-polymerase chain reaction (RT-PCR) for
C-reactive protein lg/mL 0.004 32.4 Cbfa1 expression in bovine vascular smooth muscle cells (VSMCs)
incubated in the presence of pooled sera from control or uremic subjects,
without () or with () the addition of 12 mmol/L -glycerophosphate
for 48 hours. The media [Dulbecco’s modified Eagle’s medium (DMEM)
plus serum] concentration of phosphorus (Pi) was measured at the end
3 and 4 who had minimal or no calcification (0 to 1  of the incubation period and confirmed an increase in the Pi concentra-
tion in the presence of-glycerophosphate. The results demonstrate thatno or scattered rare cells positive by Van Kossa staining).
bovine VSMC incubated with uremic serum had increased expression ofThe sample from the non-ESRD patient also had rare
Cbfa1 compared to control serum, despite similar final concentrations of
cells positive by Von Kossa, with similar Cbfa1/-actin phosphorus. Furthermore, the addition of -glycerophosphate doubled
the expression of Cbfa1 in bovine VSMCs incubated in control serum,ratio by LCM as ESRD Patients 3 and 4. These findings
but had no additive effect on bovine VSMCs incubated in uremic serum.of basal expression are consistent with basal expression
*P  0.05 compared to control.
of Cbfa1 observed by Jono et al [17] in human vascular
smooth muscle cells.
In vitro expression of Cbfa1
Bovine VSMCs were incubated in the presence of nor-
mal control human sera or uremic sera from patients on
hemodialysis for at least 2 years as previously described
[20]. As expected, the analysis of these pooled sera re-
vealed that the uremic serum had elevated levels of phos-
phorus, total and bone alkaline phosphatase, PTH, and
C-reactive protein compared to the control serum (Ta-
ble 1). However, it is important to emphasize that the
serum was subsequently diluted to 10% for use in vitro
cell cultures.
Total RNA was isolated from bovine VSMCs treated
Fig. 4. Effect of sodium/phosphate co-transport on uremic serum–with control serum or uremic serum, for 24 or 48 hours.
induced Cbfa1 expression. Reverse transcription-polymerase chain re-
RT-PCR demonstrated an increase in Cbfa1 expression action (RT-PCR) for Cbfa1 expression in bovine vascular smooth mus-
in the uremic groups compared to control serum treated cle cells (VSMCs) incubated in the presence of pooled sera from control
or uremic subjects, without or with foscarnet (an inhibitor of sodium-cells by 48 hours. The up-regulation of Cbfa1 by 48 hours
phosphate co-transport). The results demonstrate that foscarnet had
was similar to that observed with control human serum no effect on basal Cbfa1 expression and did not inhibit uremic serum
plus dexamethasone (control human  26 	 7.26; ure- induced Cbfa1. These results indicate that the effects of uremic serum
are not dependent on sodium-phosphate co-transport. *P  0.05 com-mic, 24 hours  32.3 	 7.57; uremic, 48 hours  45.3 	
pared to control.
5.78; dexamethasone  52 	 5.1; P  0.05) for uremic
48 hours and dexamethasone-treated bovine VSMCs
compared to control results pooled from three experi-
ments. To determine the role of phosphorus in uremic but had no additive effect in the uremic serum, despite a
large increase in the media concentration of phosphorusserum induced Cbfa1 expression, bovine VSMCs were
incubated in control or uremic serum with or without 12 with the addition of the -glycerophosphate (Figure 3).
Furthermore, inhibition of sodium/phosphate co-trans-mmol/L -glycerophosphate, which is cleaved to form
free phosphorus. -glycerophosphate increased the ex- port with foscarnet had no effect on Cbfa1 expression
in bovine VSMCs incubated in uremic serum (Figure 4).pression of Cbfa1 by twofold in the control human serum,
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These data support that uremic serum induces Cbfa1 ex- and all-cause mortality [25, 26]. This association of ele-
vated phosphorus levels with cardiovascular disease inpression through a nonphosphorus mediated mechanism.
vivo and Cbfa1 expression in vitro suggested that the
elevated phosphorus levels observed in uremic patients
DISCUSSION
may be the primary mechanism for increased vascular
In the present study, we have demonstrated the novel calcification. However, the results of the present in vitro
finding that the RNA and protein expression of the os- study demonstrate that uremic serum has a potent ability
teoblast differentiating factor Cbfa1 is increased in both to induce the expression of Cbfa1, over and above that
the intima and media of the inferior epigastric artery of due to hyperphosphatemia. The other uremic toxin(s)
dialysis patients with calcified vessels. This expression that may be responsible is (are) unknown. Indeed, ure-
corresponds to the expression of type I collagen and mic serum contains numerous proteins and altered forms
osteopontin proteins known to be regulated by Cbfa1. of proteins due to decreased renal clearance and incom-
The expression of Cbfa1, osteopontin, and type I colla- plete removal with dialysis. We performed a proteo-
gen was present even without overt calcification, sug- nomic analysis on the normal and uremic serum and
gesting that Cbfa1 transformation of bovine VSMC to identified 285 proteins that were increased, decreased,
osteoblast-like cells occurs prior to overt calcification. To or different in the normal versus pooled uremic serum
our knowledge, this is the first demonstration of Cbfa1 samples. Indeed, potential candidate toxins include cal-
expression in intimal and medial human arterial calcifi- citriol [27], oxidized low-density lipoprotein cholesterol
cation, supporting the hypothesis that VSMCs transform [28] and alterations of cytokines [29, 30], all of which
or dedifferentiate to osteoblast-like cells. This also lends are abnormal in the serum of dialysis patients and have
support to the hypothesis that vascular calcification is a been associated with vascular calcification in vitro or ex
regulated process. Furthermore, we have demonstrated vivo. PTH was increased in the pooled uremic serum com-
that uremic serum can up-regulate Cbfa1 through a non- pared to normal serum, however, in studies utilizing the
phosphorus-mediated mechanism, suggesting that the in vitro model used for the present study, both PTH and
etiology of vascular calcification in dialysis patients is PTHrp have been found to inhibit, not enhance, vascular
multifactorial. calcification [31]. Of note, our in vitro evidence demon-
Osteoblasts differentiate from a pluripotent mesen- strating that phosphorus is not additive to the effect of
chymal stem cell that is the progenitor for osteoblasts, other uremic factors may not reflect the in vivo state
chondrocytes, adipocytes, myocytes, and fibroblasts. The where it is likely that phosphorus and other uremic toxins
switch that controlled the differentiation to osteoblasts are additive. Supporting such a complexity, our previous
had remained elusive until the experimental findings of work demonstrated that blocking sodium-phosphate co-
the Cbfa1 knockout mice were reported [18, 19, 22]. transporter with foscarnet only partially inhibited uremic
These mice lack mineralized bone and the normal ossifi- serum-induced osteopontin expression in bovine VSMCs
cation areas in the shafts of long bones demonstrate [20]. Thus, the precise interaction of phosphorus with other
an arrest of the normal progression from cartilage to uremic toxins, and determining which uremic toxin, or
mineralized bone [19]. Subsequent studies have demon- more likely the interaction of multiple toxins, that are
strated that Cbfa1 controls the expression of the bone responsible for the induction of Cbfa1 and its protein
matrix proteins, osteopontin, type I collagen, and osteo- products will require further extensive study.
calcin in osteoblasts, by binding to osteoblast-specific Interestingly, it has been previously assumed that cal-
elements (OSE2) in the promoter region [18]. The im- cification of the media and the intima are different pro-
portance of Cbfa1 in controlling normal bone mineraliza- cesses, with macrophage infiltration of critical impor-
tion is further demonstrated by the finding that osteopro- tance in plaque formation in the intima, but not the
tegerin, the protein product of osteoblasts that controls media. We observed CD68-positive (macrophage) cells
the osteoclast, is also induced by Cbfa1 [23]. Thus, Cbfa1 in the intima of two of eight vessels from dialysis patients
is an important factor in the control of normal bone along with Cbfa1 staining. However, we found Cbfa1
turnover by regulating the deposition of type I collagen staining without CD68-positive cells in the medial layer.
and noncollagenous proteins such as osteopontin that This would imply that although there may be different
guide and control subsequent mineralization. initiation factors, calcification may ultimately proceed
Jono et al [17] first demonstrated that this osteoblast via a Cbfa1-dependent mechanism in both the intima
transcription factor Cbfa1 is expressed in vitro in cul- and media. Interestingly, the expression of Cbfa1 in the
tured human VSMCs and up-regulated in the presence intima of one vessel was adjacent to the calcified plaque,
of phosphorus at concentrations of 2 mmol/L or greater. suggesting that plaque formation may induce Cbfa1 ex-
Levels of phosphorus in this range have also been associ- pression in adjacent smooth muscle cells. As plaque for-
ated with clinical evidence of vascular calcification by mation in smaller arteries is unusual, this finding will
require confirmation. In addition, it is unknown if theseEBCT [7], and ultrasound [24], as well as cardiovascular
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